Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AMRN

Amarin Corp ADR

Sep 06 • 04:00PM ET

0.6005

Dollar change -0.0095
Percentage change -1.56	%

Healthcare • Drug Manufacturers - General • Ireland • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: SPDW GWX QQQS BIB IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.08	Insider Own	0.39%	Shs Outstand	411.11M	Perf Week	-0.94%
Market Cap	246.87M	Forward P/E	-	EPS next Y	-0.21	Insider Trans	11.09%	Shs Float	409.50M	Perf Month	-8.46%
Income	-33.45M	PEG	-	EPS next Q	-0.06	Inst Own	19.44%	Short Float	4.54%	Perf Quarter	-14.80%
Sales	265.09M	P/S	0.93	EPS this Y	-13.33%	Inst Trans	-7.25%	Short Ratio	11.81	Perf Half Y	-35.22%
Book/sh	1.34	P/B	0.45	EPS next Y	-23.53%	ROA	-4.03%	Short Interest	18.61M	Perf Year	-42.26%
Cash/sh	0.75	P/C	0.80	EPS next 5Y	38.90%	ROE	-5.97%	52W Range	0.57 - 1.37	Perf YTD	-30.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	17.93%	ROI	-5.97%	52W High	-56.17%	Beta	1.92
Dividend TTM	-	Quick Ratio	2.01	Sales past 5Y	14.60%	Gross Margin	55.41%	52W Low	5.33%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	3.04	EPS Y/Y TTM	13.44%	Oper. Margin	-14.85%	RSI (14)	38.93	Volatility	4.53% 4.77%
Employees	275	Debt/Eq	0.01	Sales Y/Y TTM	-23.65%	Profit Margin	-12.62%	Recom	3.50	Target Price	1.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	108.56%	Payout	-	Rel Volume	0.81	Prev Close	0.61
Sales Surprise	32.29%	EPS Surprise	100.00%	Sales Q/Q	-15.99%	Earnings	Jul 31 BMO	Avg Volume	1.58M	Price	0.60
SMA20	-3.94%	SMA50	-12.95%	SMA200	-31.48%	Trades		Volume	1,271,798	Change	-1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Oct-25-23	Downgrade	Jefferies	Buy → Hold	$3 → $1
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold
Nov-20-19	Initiated	Oppenheimer	Underperform	$7

Show Previous Ratings

Aug-22-24 08:30AM	Latest Research Highlighting VASCEPA /VAZKEPA (icosapent ethyl) REDUCE-IT Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress (GlobeNewswire) -5.09%
Aug-01-24 12:59PM	Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat (Zacks) -8.90%
Jul-31-24 02:15PM	Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript (Motley Fool) -12.87%
07:00AM	Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 02:26PM	3 Breakthrough Stocks Under $10 Set for Massive Upside (InvestorPlace)
04:15PM	Loading…
Jul-17-24 04:15PM	Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Portugal (GlobeNewswire)
08:00AM	Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 (GlobeNewswire)
Jul-08-24 07:30AM	Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) (GlobeNewswire)
Jun-04-24 07:30AM	Amarin Board of Directors Announces CEO Transition (GlobeNewswire) -17.91%
May-28-24 08:15AM	Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. (GlobeNewswire)
May-06-24 08:00AM	Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire) +7.69%
May-03-24 10:16AM	Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-01-24 12:35PM	Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates (Zacks) -8.86%
11:54AM	AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:00AM	Loading…
11:00AM	Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript (Motley Fool)
08:35AM	Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus (GuruFocus.com)
07:30AM	Amarin: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
Apr-24-24 02:00PM	Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event (GlobeNewswire)
Apr-22-24 08:00AM	Amarin Announces Results of Annual General Meeting of Shareholders (GlobeNewswire)
Apr-15-24 08:00AM	Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 (GlobeNewswire)
06:30AM	New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups (PR Newswire)
Apr-06-24 03:30PM	New REDUCE-IT Analyses Show VASCEPA /VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups (GlobeNewswire)
Apr-04-24 01:20PM	Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe (Zacks)
Apr-03-24 04:13PM	Why Amarin Stock Was Rocketing Higher on Wednesday (Motley Fool) +7.07%
08:00AM	Amarin Provides Update on VAZKEPA (Icosapent Ethyl) Intellectual Property Portfolio in Europe (GlobeNewswire)
Mar-25-24 08:00AM	Research Evaluating Benefits of VASCEPA/VAZKEPA (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-01-24 09:30AM	Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates (Zacks)
08:39AM	Loading…
08:39AM	Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 03:30PM	Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript (Motley Fool) -18.94%
07:37AM	Amarin: Q4 Earnings Snapshot (Associated Press Finance)
07:34AM	Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition (GuruFocus.com)
07:00AM	Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-15-24 08:00AM	Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 (GlobeNewswire)
Jan-22-24 07:30AM	Amarin Chairman & CEO Issue Letter to Shareholders (GlobeNewswire) +9.52%
Jan-12-24 09:40AM	Are Medical Stocks Lagging Amarin (AMRN) This Year? (Zacks)
Jan-11-24 09:34AM	Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results (Zacks) -9.30%
Jan-10-24 07:02PM	Why Amarin Stock Skyrocketed Today (Motley Fool) +32.87%
07:00AM	Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024 (GlobeNewswire)
Dec-26-23 07:13PM	13 Most Promising Small-Cap Stocks According to Analysts (Insider Monkey)
Dec-11-23 08:00AM	Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 12:00PM	What Makes Amarin (AMRN) a New Buy Stock (Zacks)
Nov-12-23 09:00AM	New REDUCE-IT Analyses Show VASCEPA (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline (GlobeNewswire)
Nov-02-23 10:58AM	Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.47%
Nov-01-23 12:30PM	Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript (Motley Fool)
12:03PM	Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
09:30AM	Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:25AM	Amarin Corp PLC (AMRN) Reports Q3 2023 Earnings: Net Revenues Down 27% Year-Over-Year (GuruFocus.com)
07:30AM	Amarin: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 12:00PM	Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer (GlobeNewswire)
Oct-26-23 08:00AM	Latest Research Evaluating VASCEPA /VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 (GlobeNewswire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Oct-19-23 08:00AM	Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023 (GlobeNewswire)
Sep-12-23 08:00AM	Amarin to Present at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-19-23 11:22AM	Buffett goes big on homebuilders: Insider trades & hedge funds weekly (Investing.com)
Aug-09-23 04:05PM	Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy (GlobeNewswire)
Aug-08-23 07:00AM	Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel (GlobeNewswire)
Aug-07-23 07:00AM	Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1) (GlobeNewswire)
Aug-03-23 11:22AM	Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-02-23 07:33AM	Amarin: Q2 Earnings Snapshot (AP Finance)
07:11AM	Amarin Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 08:00AM	Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey) +6.25%
Jul-26-23 08:00AM	Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress (GlobeNewswire)
Jul-25-23 04:05PM	Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain (GlobeNewswire)
Jul-20-23 08:00AM	Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt (GlobeNewswire)
Jul-19-23 12:58PM	Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss (Zacks) -24.48%
11:19AM	Why Amarin Stock Is Sinking Today (Motley Fool)
Jul-18-23 04:16PM	Amarin Appoints Patrick Holt as President and Chief Executive Officer (GlobeNewswire) +9.16%
04:15PM	Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally (GlobeNewswire)
Jul-05-23 11:43AM	Amarin (NASDAQ:AMRN) shareholders have endured a 83% loss from investing in the stock three years ago (Simply Wall St.)
Jun-21-23 09:00AM	Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA) (GlobeNewswire)
Jun-08-23 11:07AM	Investors Aren't Buying Amarin Corporation plc's (NASDAQ:AMRN) Revenues (Simply Wall St.)
Jun-01-23 04:30PM	Amarin to Present at Two Upcoming Investor Conferences (GlobeNewswire) +5.79%
06:00AM	Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China (GlobeNewswire)
May-23-23 09:50AM	3 Biotech Stocks to Avoid Like the Plague (InvestorPlace)
May-12-23 11:00AM	Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events (GlobeNewswire)
May-03-23 02:00PM	Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript (Motley Fool)
01:47PM	Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall (Zacks)
07:41AM	Amarin: Q1 Earnings Snapshot (AP Finance)
07:00AM	Amarin Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 01:32PM	Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More (Zacks)
Apr-19-23 08:00AM	Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire)
Apr-17-23 07:00AM	Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver OConnor to Companys Board of Directors (GlobeNewswire)
Apr-13-23 10:18AM	Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation (Simply Wall St.)
Apr-12-23 09:18AM	Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Apr-04-23 03:53PM	Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today (Motley Fool)
08:00AM	Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health (GlobeNewswire)
Mar-16-23 08:00AM	Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) (GlobeNewswire) +7.24%
Mar-06-23 04:05PM	Amarin Announces Board Departures (GlobeNewswire)
09:37AM	Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome (Benzinga)
08:00AM	Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC (GlobeNewswire)
Mar-05-23 10:21AM	Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event (GlobeNewswire)
Mar-03-23 11:09AM	Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-02-23 01:23PM	Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates (Zacks) -5.34%
11:44AM	Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales (Zacks)

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Berg Aaron	President and CEO	Aug 02 '24	Buy	0.64	160,000	102,400	805,380	Aug 05 05:30 PM
Holt Patrick	President and CEO	Jan 22 '24	Buy	1.09	14,426	15,724	314,426	Jan 24 04:31 PM
Ketchum Steven B	Chief Scientific Officer	Dec 12 '23	Sale	0.79	34,131	26,963	566,100	Dec 14 06:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMRN

Amarin Corp ADR

Upgrade your FINVIZ experience